LPOXY Therapeutics to Present at Biotech Showcase 2025
January 13-15, 2025, in the Hilton San Francisco Union Square, San Francisco, CA.
Platte City, MO – January 2, 2025 -- LPOXY Therapeutics, a clinical stage biopharmaceutical company dedicated to preventing bacterial infections, including Clostridioides difficile, today announced that it will present at Biotech Showcase 2025, taking place January 13-15, 2025, in the Hilton San Francisco Union Square, San Francisco, CA.
Presentation Details:
Date: Monday, January 13th, 2025
Time: 10:00 a.m. PST
Location: Biotech Showcase 2025, Franciscan C (Ballroom Level)
During the presentation, Larry Sutton, MD, PhD, CEO, will provide an overview of LPOXY’s mission to address the urgent need for innovative non-antibiotic solutions to prevent C. difficile infections, a significant and growing healthcare challenge. The discussion will highlight the substantial market opportunity presented by addressing this unmet need, driven by the high economic burden of C. difficile, which exceeds $5 billion annually in the U.S. alone. Dr. Sutton will also share the company’s clinical development plans, recent advancements, and opportunities for collaboration and investment, emphasizing how LPOXY’s approach is designed to deliver both patient and shareholder value in this historically underserved therapeutic area.
“Each year, C. difficile infections impact a half million individuals in the United States, with a significant burden on older adults,” said Dr. Sutton. “At LPOXY, we are pioneering strategies to prevent these infections and improve patient outcomes. Biotech Showcase 2025 offers an excellent opportunity to share our progress and engage with potential partners and investors as we advance our pivotal clinical trial.”
About Biotech Showcase:
BIO Partnering @ JPM Week, hosted by the Biotechnology Innovation Organization (BIO), is a premier networking event held concurrently with the JP Morgan Healthcare Conference. It facilitates partnering meetings and strategic conversations between biotech innovators, pharmaceutical leaders, and life sciences investors from around the globe.
About LPOXY Therapeutics:
LPOXY Therapeutics is a biotechnology company focused on the prevention of bacterial infections, with a primary emphasis on tackling C. difficile, a leading cause of healthcare-associated infections. Our innovative platform is designed to reduce the healthcare and economic burden associated with bacterial infections, particularly in vulnerable patient populations. With a strategic focus on impactful clinical development, LPOXY aims to deliver significant value to patients and stakeholders alike.
For more information about LPOXY Therapeutics and its development programs, please contact:
Larry Sutton, MD, PhD
CEO, LPOXY Therapeutics Inc.
Phone: +1 (816) 200-0513
Email: larry@lpoxy.com
Visit our website at www.lpoxy.com for additional details and updates.